Cargando…
The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
The four components present in the trypanocidal treatment Samorin, the commercially available formulation of isometamidium, were separated and purified by column chromatography. These compounds as well as the Samorin mixture and the other phenanthridine trypanocide, homidium, were tested on Trypanos...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356087/ https://www.ncbi.nlm.nih.gov/pubmed/30685630 http://dx.doi.org/10.1016/j.ijpddr.2019.01.003 |
_version_ | 1783391455541198848 |
---|---|
author | Eze, Anthonius A. Igoli, John Gray, Alexander I. Skellern, Graham G. De Koning, Harry P. |
author_facet | Eze, Anthonius A. Igoli, John Gray, Alexander I. Skellern, Graham G. De Koning, Harry P. |
author_sort | Eze, Anthonius A. |
collection | PubMed |
description | The four components present in the trypanocidal treatment Samorin, the commercially available formulation of isometamidium, were separated and purified by column chromatography. These compounds as well as the Samorin mixture and the other phenanthridine trypanocide, homidium, were tested on Trypanosoma congolense and wild type, diamidine- and isometamidium-resistant Trypanosoma brucei brucei strains using an Alamar blue drug sensitivity assay. EC(50) values obtained suggest that M&B4180A (2) was the most active of the components, followed by M&B38897 (1) in all the strains tested, whereas M&B4596 (4) was inactive. Samorin was found to be significantly more active than any of the individual components alone, against T. congolense and all three T. b, brucei strains. Samorin and all its active constituents displayed reduced activity against the previously characterised isometamidium-resistant strain ISMR1. |
format | Online Article Text |
id | pubmed-6356087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63560872019-02-08 The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance Eze, Anthonius A. Igoli, John Gray, Alexander I. Skellern, Graham G. De Koning, Harry P. Int J Parasitol Drugs Drug Resist Article The four components present in the trypanocidal treatment Samorin, the commercially available formulation of isometamidium, were separated and purified by column chromatography. These compounds as well as the Samorin mixture and the other phenanthridine trypanocide, homidium, were tested on Trypanosoma congolense and wild type, diamidine- and isometamidium-resistant Trypanosoma brucei brucei strains using an Alamar blue drug sensitivity assay. EC(50) values obtained suggest that M&B4180A (2) was the most active of the components, followed by M&B38897 (1) in all the strains tested, whereas M&B4596 (4) was inactive. Samorin was found to be significantly more active than any of the individual components alone, against T. congolense and all three T. b, brucei strains. Samorin and all its active constituents displayed reduced activity against the previously characterised isometamidium-resistant strain ISMR1. Elsevier 2019-01-21 /pmc/articles/PMC6356087/ /pubmed/30685630 http://dx.doi.org/10.1016/j.ijpddr.2019.01.003 Text en © 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Eze, Anthonius A. Igoli, John Gray, Alexander I. Skellern, Graham G. De Koning, Harry P. The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
title | The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
title_full | The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
title_fullStr | The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
title_full_unstemmed | The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
title_short | The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
title_sort | individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356087/ https://www.ncbi.nlm.nih.gov/pubmed/30685630 http://dx.doi.org/10.1016/j.ijpddr.2019.01.003 |
work_keys_str_mv | AT ezeanthoniusa theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT igolijohn theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT grayalexanderi theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT skellerngrahamg theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT dekoningharryp theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT ezeanthoniusa individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT igolijohn individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT grayalexanderi individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT skellerngrahamg individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance AT dekoningharryp individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance |